QLT Begins Phase III Trials of Tariquidar, a P-gp Inhibitor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 8
Volume 11
Issue 8

VANCOUVER, Canada-QLT Inc. has begun patient enrollment for two phase III clinical trials using tariquidar as an adjunctive treatment in combination with first-line chemotherapy for non-small-cell lung cancer patients, the company said in a

VANCOUVER, Canada—QLT Inc. has begun patient enrollment for two phase III clinical trials using tariquidar as an adjunctive treatment in combination with first-line chemotherapy for non-small-cell lung cancer patients, the company said in a press announcement. Approximately 1,000 patients will be enrolled at 100 centers throughout North America and Europe. The trials are designed to demonstrate the ability of tariquidar to enhance the efficacy of chemotherapy agents by preventing or overcoming resistance due to overexpression of P-glycoprotein (P-gp), a membrane protein that pumps chemotherapeutic agents out of cancer cells.

Related Videos
Related Content